Key result
Growth differentiation factor 15 (GDF-15) is discussed regarding its limitations for clinical use as a biomarker in cardiovascular disease and the need for reality checks of novel plasma biomarkers.
Discusses the limitations and potential clinical utility of GDF-15 as a biomarker in cardiovascular disease.
Limitations for a possible clinical use of GDF-15 as a biomarker in cardiovascular disease (CVD), elements to be evaluated as part of a reality check for suggested novel plasma biomarkers, and clinical settings still in urgent need for help by a biomarker. ACS = acute coronary syndrome; AMI = acute myocardial infarction; cTnT = cardiac troponin T; CTnI = cardiac troponin I, BNP = brain natriuretic peptide; NT-proBNP = N-terminal pro B-type natriuretic peptide; GDF-15 = growth differentiation factor 15.
No takes yet. Share an insight, caveat, or question.
Mueller et al. (2022) conducted a review in Cardiovascular disease. Growth differentiation factor 15 (GDF-15) was evaluated. Growth differentiation factor 15 (GDF-15) is discussed regarding its limitations for clinical use as a biomarker in cardiovascular disease and the need for reality checks of novel plasma biomarkers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: